Gut Peptides and Bone Remodeling in Children With Neuromuscular Disorders

University of Copenhagen8 enrolled

Overview

Both GIP and GLP-2 reduce bone resorption (measured as CTX) in healthy adult individuals. In this study, we will investigate whether GIP and GLP-2 reduce CTX in children with spinal muscular atrophy, duchenne muscular dystrophy, or cerebral palsy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

SINGLE

Enrollment

Conditions

Spinal Muscular Atrophy (SMA)Cerebral Palsy (CP)Duchenne Muscular Dystrophy (DMD)

Interventions

Meal testOTHER

Ingestion of an oral liquid meal (nutridrink), 3.3 mL/kg body weight.

GIP + GLP-2OTHER

Subcutaneous GIP + GLP-2 injection (1 mL containing 100 microgram GIP + 1 mL containing 400 microgram GLP-2).

PlaceboOTHER

Subcutaneous saline injection (2 mL isotonic saline).

Eligibility

Sex: ALLMin age: 10 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- Diagnosis with Cerebral palsy (CP), Duchenne muscular dystrophy (DMD) or Spinal muscular atrophy (SMA) resulting in the need of a wheelchair Exclusion Criteria: * Use of anti-resorptive medication * Confounding illnesses * Pregnancy * Allergy towards the components given on the test days * Hgb\<6.5 mmol/L

Locations (1)

Rigshospitalet

Copenhagen, Denmark

RECRUITING